Connect with us

Hi, what are you looking for?

Saturday, May 31, 2025
Mugglehead Investment Magazine
Alternative investment news based in Vancouver, B.C.
Gaize unveils cannabis impairment detection tech after large-scale clinical trial
Gaize unveils cannabis impairment detection tech after large-scale clinical trial
Cannabis impairment testing device. Photo via Gaize

Cannabis

Gaize releases ocular cannabis impairment testing device

The company will start providing the new technology to law enforcement and safety-sensitive companies by the end of 2022

A novel cannabis intoxication testing device developed by Montana tech company Gaize, Inc. detected irregular eye movement in hundreds of subjects who consumed cannabis in a recent clinical trial.

On Friday, the company revealed it had tested the ocular intoxication measurement technology on 350 participants with “outstanding” results — according to the company’s Chief Technology Officer, Rob Lass. The VR headset assessment takes about six minutes to complete.

Testing methods used in the past for cannabis can detect THC in an individual’s system weeks after use but have been unable to determine whether they are currently under the influence.

Read more: Cannabix breathalyzer to assess intoxication in a closed course driving test experiment

Read more: BYND posts 494% increase in assets and improved gross profits

The trial was completed in partnership with dicentra, a contract research organization (CRO) headquartered in Toronto. The CRO was responsible for facilitating successful data collection with the Gaize headset before and after cannabis use and ensuring that trial subjects were safe while under the influence.

Gaize plans to release the flagship product by the end of 2022 and is currently accepting reservations for it from law enforcement and businesses that have safety-critical operations.

“We have really put our cannabis impairment detection product through its paces. Based on the data we gathered, we have been able to capture important insights into how cannabis impairment manifests in eye movement,” said Rob Lass, Chief Technology Officer for Gaize.

“The impact this device could have on safety both on the road and in the workplace is for me, and everyone at dicentra, extremely exciting! We are very proud to have been a part of it and can’t wait to see the positive disruption this device brings globally,” added Peter Wojewnik, Partner at dicentra.

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Rowan Dunne on Twitter

rowan@mugglehead.com

 

 

 

 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Medical and Pharmaceutical

Cancer treatment markets are set to expand rapidly over the next decade

Stock News

Energy demand from American AI technologies was one of the factors prompting the decision

Gold

Gold producers irepresent an opportunity for the savvy investor to take advantage of the gold zeitgeist without taking out a mortgage on their house

Rare Earths

The province plans to use uranium for nuclear energy and to produce medical isotopes for treating health conditions